Drug intelligence / Profile preview

HB-201 + pembrolizumab

Development stage: Unknown
Lead developer: NeoTrail Therapeutics
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

HB-201 + pembrolizumab is a combination therapy under investigation for the treatment of cancers associated with human papillomavirus (HPV), particularly HPV16-positive tumors. HB-201 is a replication-competent, live attenuated arenavirus-based cancer immunotherapy vector developed by Hookipa Pharma. It encodes a non-oncogenic fusion protein of HPV16 E7 and E6 antigens, designed to stimulate an immune response specifically against HPV16-expressing tumor cells by inducing cytotoxic T lymphocytes[6][8]. Pembrolizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD‑1) receptor on T-cells, blocking its interaction with PD-L1/PD-L2 ligands and thereby enhancing anti-tumor immune activity[1][5]. The combination aims to leverage both direct antigen-specific immune activation (via HB‑201) and checkpoint inhibition (via pembrolizumab) for synergistic anti-cancer effects.

Other names: HB 200 programmeHB200 programmeHB-200 programmeTheraT LCMV

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on HB-201 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HB-201 + pembrolizumab.

Explore the full profile